Spyre Therapeutics shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $110 price target. Also, BTIG maintained its Buy rating and $121 price target.

Benzinga Newsdesk www.benzinga.com Positive 94.5%

Neg 0% Neu 0% Pos 94.5%

Comments

No comments yet. Be the first!